Apolipoprotein E Genotyping
Ordering Info & Methodology
Test Code
Cerner Synonyms
APOEGB
Apolipoprotein E Genotype, ApoE Genotyping, APO E Genotype, APOE, Dislipidemia, Dysbetalipoproteinemia, Dyslipidemia, Dyslipoproteinemia, Frederickson Type III, Hyperlipidemia Type III, Type III Hyperlipoproteinemia, Alzheimer, Alzheimer's, Dementia, E2, E4
Turn Around Time
Methodology
30 days
PCR and melting curve analysis, Roche LightCycler
Ordering Guide
Specimen Requirements
Sample Type
Collection Container
Alternate Collection Containers
Whole Blood EDTA
Lavender
3 mL
Add on stability
This is the length of time after sample collection that this analyte is stable. Test can be added to a previously collected sample if the time since collection is less than the add on stability time.
Minimum Volume
Add On Stability
Collection and Shipping Requirements
Send 1 unopened tube (do NOT spin or open). Refrigerate. Send on ice pack.
Reference Intervals
Female Reference Interval
Age Category | Reference Interval | units |
|---|---|---|
Male Reference Interval
Age Category | Reference Interval | units |
|---|---|---|
Additional Notes
[object Object]
Measurement Uncertainty (MU)
Every laboratory value is an estimate of the true concentration of substance. MU is the 95% confidence interval around that estimate. 95% of the time, the true concentration will be within the range of the reported value ±MU. This value is based on analytical variability (precision) and does not reflect other factors such as sample collection and handling which may also affect the result.
Example
Reported sodium = 140 mmol/L
Sodium MU = 1%
Expanded uncertainty = 140 mmol/L ± 1% or 140mmol/L ± 1.4 mmol/L
Interpretation - the true value of sodium in the sample is in the range 138.6-141.4 mmol/L, with 95% confidence.
Measurement Uncertainty
For investigation of type III dyslipidemia (dysbetalipoproteinemia) E2E2 genotype: prior consultation is required and/or referring labs must provide lipid panel results.
For risk assessment for amyloid-related imaging abnormalities (ARIA) in the context of amyloid-targeting therapies for Alzheimer’s disease:
Only orderable by physicians that specialize in dementia care, e.g., neurologists, geriatricians, and psychiatrists
Testing is permitted only for individuals with biomarker evidence of Alzheimer’s disease pathology (e.g., from CSF amyloid-beta and tau testing--see our Neurodegenerative Profile test)
Genotyping is not permitted for the assessment of risk for developing Alzheimer’s disease; orders for patients without documented biomarker evidence of Alzheimer’s pathology will be cancelled.